Iron Toxicity Logo

For Health Care Professionals
Outside the U.S. Only

U.S. Patients

For U.S/ Healthcare Professionals

Screening and Monitoring
FOR IRON OVERLOAD

Accurate assessment of body iron burden is necessary, not only to diagnose iron overload but also to effectively manage therapy. In addition, given the late onset of clinical symptoms after substantial organ damage has already occurred, it is important that an accurate, non-invasive, readily available screening test for iron overload is available.

A variety of tests are available to assess iron burden and its functional effects. Laboratory tests such as serum ferritin can be used for both screening and monitoring, especially when performed repeatedly over a period of time. Imaging studies such as magnetic resonance imaging (MRI) can detect hepatic and cardiac iron deposition, and may be useful in the assessment of hepatic iron burden. For patients with diagnosed or strongly suspected iron overload, liver biopsy remains the most quantitatively accurate, sensitive, and specific test for liver iron concentration. The use of two or more tests will usually be required to define the patient's iron burden and distribution in tissues (1).

Diagnosing iron overload in HH

The diagnosis of iron overload secondary to hereditary hemochromatosis (HH), can be made using several modalities:

  • Laboratory tests: Serum ferritin >200 mcg/L in premenopausal women and >300 mcg/L in men and postmenopausal women combined with serum transferrin saturation (fasting value >50% in women and >60% in men) is a sensitive marker for excess iron (2,3). In confirmed HH serum ferritin >1000 mcg/L is an accurate predictor of the degree of hepatic fibrosis (cirrhosis) (4).
  • Imaging studies: MRI may detect hepatic iron stores (5).
  • Biopsy:Liver biopsy was at one time the gold standard for assessment of iron overload. However, among patients with hereditary iron overload it now mainly serves in the evaluation of cirrhosis.

Diagnosing transfusional iron overload

Because transfusions may lead to rapid iron accumulation, monitoring a patient's number of transfused blood units, serum ferritin levels, and/or liver iron concentrations can play an essential role in the management of iron overload (6,7).

Overview of iron overload tests

`
Method Advantages Disadvantages
Serum ferritin Non-invasive
Can be performed frequently, allowing regular monitoring
Inexpensive (commercial kits available)
Positive correlation with morbidity and mortality
Allows longitudinal follow-up
Indirect measurement of iron burden
Levels are influenced by many factors, including nutrition, infection, and inflammation
Serial measurement and/or combination with other indicators is required
Liver biopsy Validated reference standard
Direct measurement that provides accurate information
Allows non-heme storage iron to be measured
Allows accurate assessment of disease progression
Positive correlation with morbidity and mortality
Invasive, painful, potentially serious complications
Requires skilled professional personnel and standardized laboratory procedures
Small biopsy may not be representative of tissue iron distribution
Spurious measurements may occur as a result of certain hepatic diseases
Poorly correlated with cardiac iron
Difficult follow-up
MRI Non-invasive
Able to analyze whole organ
Pathologic status of the liver can be assessed in parallel
Allows longitudinal follow-up of patients
Requires imager with a dedicated imaging method
Indirect measurement of LIC
SQUID Non-invasive
Measurement may be repeated frequently
Linear correlation with LIC assessed by biopsy
Limited availability
High cost
Indirect measurement of LIC
Complex procedure requiring trained personnel
Underestimates LIC versus biopsy

Serum ferritin

The most commonly used test for iron overload is serum ferritin. Inexpensive, noninvasive, and widely available, it provides reliable estimates of iron burden when performed on a serial basis. Serum ferritin levels consistently >1000 mcg/L are suggestive of iron overload (6,8), and in the absence of appropriate therapy are associated with adverse clinical outcomes in both transfusional iron overload(9,10) and hereditary hemochromatosis (11).

More about serum ferritin testing for iron overload

Liver biopsy

Liver biopsy provides direct information about the structure, function, and extent of iron deposition within the liver, and may also have prognostic value.

More about liver biopsy testing for iron overload

Magnetic resonance imaging

MRI provides a non-invasive alternative to liver biopsy, and may be more accurate than biopsy in patients with heterogeneous liver iron deposition (such as those with cirrhosis) since it measures iron in the whole organ.

More about MRI testing for iron overload

Cardiac biopsy

A cardiac biopsy enables the histologic assessment of heart tissue changes and iron loading in patients with iron overload. However, like the liver, the distribution of stored iron in the heart is not homogeneous, so the test may not provide a true estimate of iron content, particularly in the early stages of disease (12). In addition, the invasive approach can result in serious complications (13), meaning that the use of cardiac biopsy is primarily restricted to the research rather than the clinical setting. Other methods available for assessing cardiac iron levels include MRI and the determination of cardiac function — using echocardiography and multiple-gated acquisition scanning for example.

Quantitative phlebotomy

Although not feasible for transfusion-dependent patients, quantitative phlebotomy is the reference method for assessing iron storage in patients with hereditary hemochromatosis (14). It cannot be used in anemic patients, however, and its cost, inconvenience, and side effects limit its use.

LVEF imaging studies

Accurate assessments of left ventricular ejection fraction (LVEF) can be provided noninvasively by resting or stress echocardiography (15,16) or radionuclide ventriculography (17,18). These studies may be useful in the diagnosis of early iron-induced cardiac disease, since diastolic dysfunction has been shown to be of prognostic value in the development of symptomatic iron-induced cardiac disease (19).

Print

In This Section

On This Page

About Novartis Oncology

Our primary goal is to research and develop new methods to treat cancer better than is possible today.

Learn more

In This Section

Laboratory tests

Learn more about the accuracy, advantages, and disadvantages of lab tests for iron overload, including serum ferritin, serum transferrin saturation, and exploratory lab tests.

Imaging studies

Learn more about the accuracy, advantages, and disadvantages of MRI and SQUID for diagnosing and monitoring iron overload.

Liver biopsy

Learn more about the advantages, disadvantages, and prognostic value of liver biopsy, the reference standard test for iron overload.

References

  • * (1)Borgna-Pignatti C, Castriota-Scanderbeg A, Methods for evaluating iron stores and efficacy of chelation in transfusional hemosiderosis. Haematologica. 1991;76(5):409-13.
  • * (2)Edwards CQ, Griffen LM, Kaplan J, et al, Twenty-four hour variation of transferrin saturation in treated and untreated haemochromatosis homozygotes. J Intern Med. 1989;226(5):373-9.
  • * (3) Borwein S, Ghent CN, Valberg LS. Diagnostic efficacy of screening tests for hereditary hemochromatosis. Cen Med Assoc. 1984;131:895-901.
  • * (4) Bassett ML, Halliday JW, Powell LW, Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology. 1986;6(1):24-9.
  • * (5) Guyader D, Jacquelinet C, Moirand R, et al. Non-invasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998;115:929-36.
  • * (6) Perifanis V, Economou M, Christoforides A, et al, Evaluation of iron overload in beta-thalassemia patients using magnetic resonance imaging. Hemoglobin. 2004;28(1):45-9.
  • * (7)Porter JB, Practical management of iron overload. Br J Haematol. 2001;115(2):239-52.
  • * (8)Olivieri NF, Brittenham GM, Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739-61.
  • * (9)Andrews NC, Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986-95.
  • *(10)Porter JB, Practical management of iron overload. Br J Haematol. 2001;115(2):239-52.
  • (11) National Institutes of Health, National Heart, Lung, and Blood Institute: The Management of Sickle Cell Disease. 2002, Bethesda, MD: NIH.
  • * (12)Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome [editorial]. Haematologica. 2006;91:1588-90.
  • * (13)Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007;78:487-94.
  • * (14) Morrison ED, Brandhagen DJ, Phatak PD, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med. 2003;138:627-33.
  • * (15)Olson LJ, Edwards WD, McCall JT, et al, Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol. 1987;10(6):1239-43.
  • * (16)Liu P, Olivieri N, Iron overload cardiomyopathies: new insights into an old disease. Cardiovasc Drugs Ther. 1994;8(1):101-10.
  • (17) Bothwell T, Charlton RW, Cook JD, et al, in Iron Metabolism in Man. 1979, Blackwell Scientific Publications: Oxford. p. 105-15.
  • * (18)Ward RP, Mor-Avi V, Lang RM, Assessment of left ventricular function with contrast echocardiography. Cardiol Clin. 2004;22(2):211-9.
  • * (19) Gillespie ND, Struthers AD, Pringle SD, The assessment of left ventricular function by echocardiography. Scott Med J. 1995;40(5):132-3.
  • * (20) Brenta G, Mutti LA, Schnitman M, et al, Assessment of left ventricular diastolic function by radionuclide ventriculography at rest and exercise in subclinical hypothyroidism, and its response to L-thyroxine therapy. Am J Cardiol. 2003;91(11):1327-30.
  • * (21)Topuzovic N, Worsening of left ventricular diastolic function during long-term correction of anemia with erythropoietin in chronic hemodialysis patients--an assessment by radionuclide ventriculography at rest and exercise. Int J Card Imaging. 1999;15(3):233-9.
  • * (22) Hou JW, Wu MH, Lin KH, et al, Prognostic significance of left ventricular diastolic indexes in beta-thalassemia major. Arch Pediatr Adolesc Med. 1994;148(8):862-6.

Contact Us | Site Map | About Novartis Oncology | Privacy Policy

Novartis Oncology Logo

Use of this website is subject to our Terms of Use and © 2010 Novartis AG.